Nucana Stock Soars 25% on Positive Melanoma Study Results

Nucana's stock surged 25% in pre-market trading on June 6, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Nucana's stock has seen a remarkable surge of 151% following the release of positive efficacy data from a mid-stage melanoma study. The study, which involved the combination of NUC-7738 and Merck's Keytruda, has shown promising results, driving investor optimism and contributing to the stock's recent gains.

Analysts have also weighed in on Nucana's prospects, with the most recent rating being a Buy, accompanied by a price target of $150.00. This positive outlook from analysts further supports the bullish sentiment surrounding the company's stock.